Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in relapsed or refractory primary or secondary CNS lymphoma
CTR20190854Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in central nervous system lymphoma, primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), sponsored by Innovent Biologics. Started Jun 2019; status: active.
02
Drugs
orelabrutinib
03
Conditions
central nervous system lymphomaprimary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on CTR20190854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190854.